What's Going On With Monopar Therapeutics

 

• Monopar Therapeutics Inc 
  MNPR+0.55%+ Free Alerts
   opened enrollment for the fifth dose level cohort in the open-label Phase 1b camsirubicin Maximum Tolerated Dose trial for advanced soft tissue sarcoma (ASTS), a diverse type of cancer that typically develops in the body's connective tissue. 
• The cohort dose is at an increased dose of 650 mg/m2, nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial.
• The company said that no drug-related cardiotoxicity has been observed with camsirubicin treatment. 
• It compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin treatment, the current first-line treatment for ASTS.
• 17% of camsirubicin patients in the trial have experienced low-grade hair loss; another 8% have experienced over 50% hair loss, versus approximately 50% of doxorubicin-treated patients reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss.
• 8% of camsirubicin patients in the trial have experienced low-grade mild oral mucositis compared to the roughly 35-40% of doxorubicin-treated patients.
• "So far, camsirubicin has demonstrated a favorable safety profile at up to the 520 mg/m2 dose level assessed to date," said Dr. Cranmer."
• EF Hutton writes that having established proof-of-concept in sarcoma, camsirubicin could be developed in another dozen cancer indications, where doxorubicin is still the backbone of treatment.
• It reiterates the Buy rating and a price target of $24.

https://www.benzinga.com/general/biotech/23/02/30906428/whats-going-on-with-monopar-therapeutics-shares-today